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Patrick VAN UDEN1, Niall S. KENNETH1 and Sonia ROCHA2
College of Life Sciences, Wellcome Trust Centre for Gene Regulation and Expression, MSI/WTB/JBC Complex, Dow Street, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
HIF (hypoxia-inducible factor) is the main transcription factor
activated by low oxygen tensions. HIF-1α (and other α subunits)
is tightly controlled mostly at the protein level, through the
concerted action of a class of enzymes called PHDs (prolyl
hydroxylases) 1, 2 and 3. Most of the knowledge of HIF
derives from studies following hypoxic stress; however, HIF-1α
stabilization is also found in non-hypoxic conditions through
an unknown mechanism. In the present study, we demonstrate
that NF-κB (nuclear factor κB) is a direct modulator of HIF-1α
expression. The HIF-1α promoter is responsive to selective NF-
κB subunits. siRNA (small interfering RNA) studies for indivi-
dual NF-κB members revealed differential effects on HIF-1α
mRNA levels, indicating that NF-κB can regulate basal HIF-1α
expression.Finally,whenendogenousNF-κBisinducedbyTNFα
(tumour necrosis factor α) treatment, HIF-1α levels also change
in an NF-κB-dependent manner. In conclusion, we ﬁnd that NF-
κB can regulate basal TNFα and, in certain circumstances, the
hypoxia-induced HIF-1α.
Key words: hypoxia, hypoxia-inducible factor 1 (HIF-1), nuclear
factor κB (NF-κB), tumour necrosis factor (TNF).
INTRODUCTION
HIF (hypoxia-inducible factor) plays key roles in development,
physiological processes and pathological conditions as its
presence affects survival, cell-cycle progression and metabolism
[1,2]. Although ﬁrst identiﬁed as the main transcription factor
activated under low oxygen tensions, HIF is a key transcription
factor activated by cytokines, oncogenes and ROS (reactive
oxygen species) under normoxic conditions [3]. HIF is a
heterodimeric factor composed of α and β subunits [also called
ARNT (aryl hydrocarbon nuclear translocator)] [1]. Although
HIF-1β is constitutively expressed and not regulated by oxygen
levels, HIF-α subunits are tightly controlled at the protein level.
This occurs, predominantly, through the concerted action of a
class of enzymes called PHDs (prolyl hydroxylases) that catalyse
prolyl hydroxylation of HIF-α subunits, which incessantly targets
them for VHL (von Hippel–Lindau protein)-dependent 26S
proteasomal degradation [4]. PHD enzymes require molecular
O2, 2-oxoglutarate, iron ions (Fe
2+) and ascorbic acid to be fully
active, and are inhibited in hypoxic conditions [4].
Four PHDs have been identiﬁed so far, but only three, PHDs
1, 2 and 3, have been functionally characterized in terms of HIF
modulation [4]. PHD2 is thought to be the dominant PHD in
controlling HIF-1α following hypoxia [5]. Furthermore, all three
PHDs can be regulated by HIF and by oxygen levels [6–8].
In addition to the HIF-α stabilization mechanism controlled by
prolylhydroxylation,hydroxylationofAsn
803 inHIF-1α orAsn
851
in HIF-2α, prevents interaction with the CH1 domains of histone
acetyltransferases{p300/CBP[CREB(cAMP-response-element-
binding protein)-binding protein]} that act as transcriptional co-
activators. This modiﬁcation alters the ability of HIF-1/HIF-2 to
transactivate their target genes [9]. Although most knowledge
regarding HIF-1 has been derived from studies following
hypoxic stress, HIF-1 stabilization has also been found in non-
hypoxic settings, such as relatively well-oxygenated regions
of tumours, and in diseases such as rheumatoid arthritis and
diabetes [10,11]. However, the mechanisms for HIF stabilization
under those conditions have not been elucidated. Many of
the stimuli that induce HIF-1 in normoxia are known to
activate a number of other transcription factors such as NF-κB
(nuclear factor κB). It is therefore plausible that cross-talk be-
tween these two transcription factors can occur. In addition, the
HIF-1α andPHD1promoterscontainNF-κB-bindingsites,which
have not been functionally characterized. Importantly, HIF-1α
stabilization and induction through H2O2 was recently shown to
be NF-κB dependent under normoxic conditions [12].
NF-κB is the collective name for a transcription factor that
exists as either a hetero- or homo-dimer and is formed by a family
of subunits called RelA (p65), RelB, cRel, p50 and its precursor
p105 (NF-κB1), and p52 and its precursor p100 (NF-κB2). Some
dimers are more prevalent than others and they shuttle between
the cytoplasm and nucleus but are predominantly sequestered
in the inactive state in the cytoplasm, inhibited by members of the
IκB (inhibitor of NF-κB) [13]. Upon stimulation, by compounds
such as TNFα (tumour necrosis factor α), oncogenes or UV
light, a kinase signalling cascade results in phosphorylation of
IκB,signallingubiquitination-mediatedproteasomaldegradation,
resulting in NF-κB release and translocation into the nucleus
[13,14]. The activated NF-κB dimer then binds to target DNA
sequences in the nucleus where it regulates transcription of
NF-κB target genes. Although NF-κB activation is extremely
fast, the cyclic nature of NF-κB activity, in combination with
post-translational modiﬁcations and hyper- and hypo-acetylated
histones at target genes are indicative of further levels of
regulatory complexity [15].
There have been several studies demonstrating cross-talk
between the NF-κB and HIF signalling pathways, including
shared target genes, but a direct link has yet to be elucidated.
In the present study, we show that several NF-κB subunits are
boundtotheHIF-1αpromoter.NF-κBdepletionresultsinreduced
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basal levels of HIF-1α mRNA. In addition, we demonstrate
that TNFα-induced NF-κB can increase HIF-1α mRNA, protein
and activity levels, leading to transactivation of target genes in
normoxia. Changes in HIF-1α levels following hypoxia are only
seen when the NF-κB pathway is completely blocked. These
results demonstrate that NF-κB can directly modulate the HIF-1α
pathway, and that this modulation is sufﬁcient to alter HIF target
gene expression in vivo.
MATERIALS AND METHODS
Tissue culture, medium and hypoxia treatments
U2OS osteosarcoma and HEK (human embryonic kidney)-
293 cell lines were obtained from the European Collection of
Cell Cultures. IKK (IκB kinase) wild-type, IKKα
−/−, IKKβ
−/−
and IKKα/β
−/− mouse embryonic ﬁbroblasts were a gift from
Professor Inder Verma (Laboratory of Genetics, The Salk
Institute for Biological Studies, La Jolla, CA, U.S.A.). All cells
were grown in DMEM (Dulbecco’s modiﬁed Eagle medium;
Lonza) supplemented with 10% fetal calf serum (Gibco),
50 units/ml penicillin (BioWhittaker) and 50 μg/ml streptomycin
(BioWhittaker) for no more than 30 passages. For hypoxia
treatments, cells were placed in 1% O2 using an InVivo 300
workstation (Ruskin).
siRNA (small interfering RNA) transfection and sequences
siRNA duplex oligonucleotides were synthesized by MWG and
transfected using Interferin (Polyplus) following the manufac-
turer’s protocol. The oligonucleotides used were: Control, 5
 -AA-
CAGUCGCGUUUGCGACUGG-3
  [16]; RelA, 5
 -GCUGAUG-
UGCACCGACAAG-3
  [16]; RelB, 5
 -AAUUGGAGAUCAU-
CGACGAGU-3
 ; p50/p105, 5
 -AAGGGGCUAUAAUCCUGG-
ACU-3
 ; p52/p100, 5
 -AAGAUGAAGAUUGAGCGGCCU-3
 
[17]; HIF-1α,5
 -CUGAUGACCAGCAACUUGA-3
 ; IKKα,
5
 -GCAGGCUCUUUCAGGGACA-3
 ; and IKKβ,5
 -CAGG-
UGAGCAGAUUGCCAU-3
 . The cRel siRNA sequence was as
described previously [17].
DNA constructs
Individual NF-κB subunit expression vectors were a gift from
Professor Neil Perkins (Division of Gene Regulation and
Expression, College of Life Sciences, University of Dundee,
Dundee, Scotland, U.K.). HIF-1α promoter luciferase constructs
were a gift from Dr Carine Michiels (Department of Biology,
University of Namur, Namur, Belgium).
Antibodies
Antibodies against HIF-1α, (R&D Systems), RelA (p65), RelB,
cRel, p50 (NF-κB1), Chk1 (checkpoint kinase 1) and p52 (NF-
κB2) were from Santa Cruz Biotechnology. Antibodies against
GLUT (glucose transporter) 1/3 were from Neomarkers,
against HIF-2α were from Novus Biologicals, against HIF-1β,
IKKα and IKKβ were from Cell Signalling, against β-actin
and PCNA (proliferating-cell nuclear antigen) were from Sigma,
against PHD2 were from Abcam, and against Bcl-XL were from
Merck Biosciences. Enhanced chemiluminescence (Pierce) was
used for detection.
qRT-PCR (quantitative reverse transcriptase PCR)
qRT-PCR was carried out in a 25 μl total reaction mixture with
1 μl of extracted RNA sample (10 pg–100 ng), 12.5 μlo fO n e -
Step RT (reverse transcriptase) qPCR master mix Plus for SYBR
Figure 1 NF-κB subunits can activate the HIF-1α promoter
(a) Schematic diagram of the HIF-1α promoter–luciferase constructs. (b) HEK-293 cells were
co-transfected with 1μgo fH I F - 1 α promoter–luciferase constructs and 1 μg of each of the
NF-κBsubunits.Luciferaseactivitywasmeasured48 hpost-transfection.Valuesaremeans+S.D.
for a minimum of three independent experiments performed in duplicate. The y-axis shows the
fold activation above control plasmid. (c) NF-κB subunits bind to the κB site in the HIF-1α
promoter. HEK-293 cells were transfected with 2μg of each of the NF-κB subunits, nuclear
extracts were prepared, and the DNA-binding activity was measured by EMSA using a speciﬁc
probefortheHIF-1αpromoter.(d)Nuclearextractswerepreparedasin(c),andtheDNA-binding
activity was measured using a canonical NF-κB target promoter, HIV. (e) Nuclear extracts were
analysed by Western blot for the individual NF-κB subunits.
Green I (Eurogentec), 0.2 μM forward primer, 0.2 μMr e v e r s e
primer, 0.125 units/ml EuroScript RT and 10.875 μlo fR N a s e -
free distilled water. Ampliﬁcation and detection were performed
using a Rotor-Gene 3000 (Corbett Research) and IQ5 Icycler
(Bio-Rad) detection system under the following conditions: an
initial reverse transcription at 48◦C for 30 min, followed by PCR
activation at 95◦C for 10 min and 45 cycles of ampliﬁcation (15 s
at 95◦C and 1 min at 58◦C). During ampliﬁcation, a detector
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Figure 2 Endogenous NF-κB subunits control basal HIF-1α mRNA levels
(a) HEK-293 cells were transfected with the indicated siRNA oligonucleotides, and qRT-PCR
was performed. The histogram depicts the relative levels of HIF-1α mRNA normalized to
actin mRNA levels. The mean+S.D. were calculated from a minimum of three independent
experiments.AStudent’st testwasperformedand*P <0.050and**P <0.010whencompared
with the control. Actual P values are: RelA, P =0.012; RelB, P =0.012; c-Rel, P =0.076;
p50, P =0.348; p52, P =0.035; HIF-1α, P =0.007. (b) ChIP analysis using the indicated
antibodiesandPCRanalysisusingspeciﬁcprimersfortheHIF-1αpromoterandHIF-1α control
region was performed.
monitoredreal-timePCRampliﬁcationbyquantitativeanalysisof
the ﬂuorescence emissions. Sample values obtained with speciﬁc
primer sets were normalized to β-actin primer set values.
qRT-PCR primer sequences
For qRT-PCR, the following primer sequences were used: β-actin
forward,5
 -GTGGGAGTGGGTGGAGGC-3
  andreverse,5
 -TC-
AACTGGTCTCAAGTCAGTG-3
 ; 18S forward, 5
 -AAACGG-
CTACCACATCCAAG-3
  and reverse, 5
 -CGCTCCCAAGATC-
CAACTAC-3
 ; GLUT1 forward, 5
 -GATTGGCTCCTTCTCT-
GTGG-3
  and reverse, 5
 -TCAAAGGACTTGCCCAGTTT-3
 ;
GLUT3forward,5
 -CAATGCTCCTGAGAAGATCATAA-3
  and
reverse, 5
 -AAAGCGGTTGACGAAGAGT-3
 ; HIF-1α forward,
5
 -CATAAAGTCTGCAACATGGAAGGT-3
  and reverse, 5
 -AT-
TTGATGGGTGAGGAATGGGTT-3
 ; and HIF-2α forward, 5
 -
GCGCTAGACTCCGAGAACAT-3
  and reverse, 5
 -TGGCCA-
CTTACTACCTGACCCTT-3
 .
ChIP (chromatin immunoprecipitation)
Proteins were cross-linked with formaldehyde for 10 min.
After adding 0.125 mol/l glycine, cell lysis buffer [1% SDS,
10 mM EDTA, 50 mM Tris/HCl (pH 8.1), 1 mM PMSF, 1 mg/ml
leupeptin and 1 mg/ml aprotonin] was added, followed by sonic-
ation and centrifugation (13000 g for 10 min at 4◦C). The super-
natant was precleared with sheared salmon sperm DNA and
Protein A–Sepharose beads (Sigma). The supernatant was incub-
ated with speciﬁc antibodies overnight, and then with Protein
A–Sepharose beads for 1 h. After an extensive wash step, the
complexes were eluted with buffer (100 mmol/l sodium bicarbo-
nate and 1% SDS) and incubated with proteinase K. DNA
was puriﬁed using the QIAquick PCR puriﬁcation kit (Qiagen).
PCR was performed with primers for the HIF-1α promoter
Figure 3 NF-κB subunits control basal levels of HIF-1α protein
(a) HEK-293 cells were transfected with the indicated DNA constructs, and whole cell lysates
wereobtained48 hpost-transfection.At3hpriortoharvest,halfofthesampleswereincubated
with 50μM MG132. Western blot analysis for the indicated proteins was then performed on
these extracts. (b) HEK-293 cells were transfected with the indicated siRNA oligonucleotides,
and whole cell lysates were obtained 48h post-transfection. At 3h prior to harvest, half of the
samples were incubated with 50 μM MG132. Western blot analysis for the indicated proteins
was then performed on these extracts.
(forward, 5
 -GAACAGAGAGCCCAGCAGAG-3
  and reverse,
5
 -CCTGAGGTGGAGGCGGGTTC-3
 ) ﬂanking the NF-κB-
bindingsite(−197/188 bp)at64◦Cannealingand72◦Cextension
for 32 cycles. This primer set spans from −536 to −137 bp from
the transcription start site. The HIF-1α control primer set was
5
 -TGCTCATCAGTTGCCACTTC- 3
  (forward) and 5
 -AAAA-
CATTGCGACCACCTTC-3
  (reverse). This primer set is located
in the gene itself, 24937 bp away from the transcription start
site. The primers used for HIF-1α target genes promoters were:
VEGF (vascular-endothelial growth factor) forward, 5
 -ACGTT-
CCTTAGTGCTGGCGGGTAGGTTTGA-3
  and reverse, 5
 -GC-
ACCAAGTTTGTGGAGCTGAGAACGGG-3
 ; CA9 forward,
5
 -GACAAACCTGTGAGACTTTGGCTCC-3
  and reverse, 5
 -
AGTGACAGCAGCAGTTGCACAGTG-3
 ; and DEC1 forward,
5
 -CACGTGAGACTCATGTGATGAAGCC-3
  and reverse, 5
 -
AAGCCGAGGAGTAATGGAGAGGCT-3
 .
Other experimental procedures
Luciferase assays, whole cell protein, nuclear extracts and EMSA
(electrophoretic mobility-shift assay) analysis were performed as
described previously ([17a] and references therein). RNA was
extracted using a nucleospin RNA II kit (Machery-Nagel). The
EMSA probe used for HIF-1ακ B site was 5
 -GCGTGGGCTG-
GGGTGGGGACTTGCCGCCTGCGTCGC-3
 .
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Figure 4 TNFα treatment induces NF-κB and HIF-1α
(a) HEK-293 cells were treated with 10ng/ml TNFα for the indicated times, nuclear extracts were prepared, and these extracts were analysed by Western blot for the indicated proteins. PCNA was
usedasaloadingcontrol.(b)Cellsweretreatedasin(a),andcellextractswereanalysedbyWesternblotfortheindicatedHIF-1α targets.(c)Cellsweretreatedasin(a),butmRNAwasextractedand
qRT-PCRwasperformedfortheindicatedgenetranscripts.ThehistogramdepictsrelativelevelsofspeciﬁcmRNAtranscriptsnormalizedtoactinmRNAlevels.Themean+S.D.werecalculatedfrom
a minimum of three independent experiments. (d) Cells were transfected with the indicated siRNA oligonucleotides and treated with 10ng/ml TNFα, 24h prior to total mRNA extraction. qRT-PCR
w a sp e r f o r m e da si n( c).
RESULTS
Differential control of the HIF-1α promoter by NF-κB subunits
The HIF-1α promoter was originally cloned in 1996 [18] and a
study by Michiels and co-workers [19], identiﬁed several binding
sites for transcription factors such as AP-1 (activator protein 1)
and NF-κB [19]. Given the advance in our knowledge of NF-κB
consensus sites [14], we reanalysed the HIF-1α promoter (http://
www.genomatix.de/products/MatInspector). This analysis iden-
tiﬁed a putative NF-κB-binding site located −197/188 bp from
the initiation site (Figure 1a). Using HIF-1α promoter reporter
constructs either with or without the putative NF-κB-binding
site [19], we investigated the contribution of individual NF-κB
subunits in normoxia (Figures 1a and 1b). All NF-κB subunits
could activate the HIF-1α promoter, with the highest effect being
observedwithp50andthelowesteffectwithp52.Incontrast,none
of the NF-κB subunits activated a truncated version of the HIF-
1α promoter construct which lacks the NF-κB site (Figure 1b).
To investigate whether NF-κB could bind the putative site on the
HIF-1α promoter, we performed EMSAs using nuclear extracts
derived from HEK-293 cells which had been transfected with the
individual NF-κB subunits (Figure 1c). We could detect intense
binding by p50, and weaker binding by p65, c-Rel and p52. No
visible binding could be observed with RelB, although the ex-
pression levels were comparable (Figure 1e). Binding to the
canonical site in the HIV promoter was used to assess the NF-κB
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Figure 5 TNFα induces HIF-1α activity in an NF-κB-dependent manner
(a) HEK-293 cells were transfected with the indicated siRNA oligonucleotides, treated with 10ng/ml TNFα 24h prior to harvest, and whole cell lysates were prepared. Extracts were analysed by
Western blot using the indicated antibodies. (b) ChIP analysis using the indicated antibodies and PCR of speciﬁc regions of the HIF-1α target genes, VEGF, CA9 and DEC1. HRE, hypoxia-response
element. (c)A si n( b) but the HIF-1α promoter and control regions were analysed. (d) Cells were treated as in (a), and Western blot analysis was performed using the indicated antibodies. PCNA
was used as a loading control.
binding ability (Figure 1d). These results suggest that NF-κBi s
able to regulate HIF-1α promoter activity.
NF-κB modulates basal HIF-1α mRNA levels
To investigate whether endogenous NF-κB could modulate the
HIF-1α promoter, siRNA oligonucleotides directed towards
the different NF-κB subunits were used. The siRNA sequences
have been previously validated [16,17]. qRT-PCR analysis
demonstrated that endogenous NF-κB regulated basal HIF-1α
mRNA levels (Figure 2a). Interestingly, reduction of p50 levels
had no effect on HIF-1α mRNA levels, possibly indicating a
compensatory action by p52 or other NF-κB subunits. The co-
operation between p50 and p52 is best depicted in the genetic
knockout mice, where p50 and p52 single deletions showed no
developmental defects, whereas double deletion of these genes
resulted in severe impairment in bone development [20,21].
Endogenous p65, RelB and p52 have the highest effect on HIF-
1α mRNA levels (Figure 2a). Despite inducing a slight reduction
in HIF-1α mRNA, c-Rel depletion did not induce statistically
signiﬁcant effects (Figure 2a). To assess whether NF-κBi s
directly regulating HIF-1α mRNA levels, ChIP analysis was
performed. Several of the NF-κB subunits could be found at
the HIF-1α promoter; however, we could not detect any NF-
κB binding in a control region of the gene (Figure 2b). This
demonstrates that NF-κB modulates the basal level of HIF-1α
mRNA directly.
NF-κB modulates HIF-1α protein levels in normoxia
HIF-1α is predominantly regulated at the protein level following
hypoxia [22]. Since the studies in the present paper were con-
ducted at normal oxygen levels, PHD activity is not readily
inhibited.ToinvestigatewhetherNF-κBcouldalsomodulateHIF-
1α protein levels NF-κB overexpression and siRNA-mediated
knockdowns were used. Given that HIF-1α protein is rapidly
degraded at normal oxygen levels, only small changes could be
expected. It was possible to observe increases in protein levels
when all of the NF-κB subunits were overexpressed (Figure 3a).
However, RelA and c-Rel induced the highest increase followed
by p50, p52 and RelB. Changes in HIF-1α protein were best
visualized when the proteasome inhibitor MG132 was used
(Figure 3a). Conversely, a small reduction of HIF-1α protein
levelscouldbeobservedwhenRelA,RelBandp52weredepleted.
A small effect was also evident when c-Rel was depleted but
no effects could be detected with p50 depletion (Figure 3b). In
either overexpression or siRNA-mediated knockdown of NF-κB
subunits, HIF-1β levels remained stable (Figure 3).
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Figure 6 Complete inhibition of NF-κB impairs hypoxia induced HIF-1α levels
(a) U2OS cells were transfected with the IKKα or IKKβ siRNA oligonucleotides and exposed to 1% O2 for the indicated times prior to harvest. Whole cell lysates were analysed by Western blot.
(b) Wild-type, IKKα−/− and IKKβ−/− mouse embryonic ﬁbroblasts were exposed to 1% O2 for the indicated periods of time, and whole cell lysates were prepared. Extracts were analysed by
Western blot. (c) Wild-type and IKKα/β−/− mouse embryonic ﬁbroblasts were exposed to 1% O2 for the indicated periods of time, and whole cell lysates were prepared. Extracts were analysed
by Western blot. (d) U2OS cells were left untreated or treated for 4h with 1% O2 prior to harvest, and ChIP analysis using the indicated antibodies was performed. PCR analysis using speciﬁc
primers for the HIF-1α promoter and HIF-1α control region was performed.
TNFα-induced NF-κB modulates HIF-1α expression
Activation of NF-κB is best associated with inﬂammatory
responses [13]. It is rapidly activated following cytokines such
as TNFα or bacterial products such as LPS (lipopolysaccharide).
In fact, these stimuli have both been described to activate HIF-1α
as well, although the mechanism has not been fully elucidated
[23,24]. Given that prolonged TNFα exposure is present in
many inﬂammatory diseases and certain cancers, we investigated
whether HIF-1α was induced under such conditions (Figure 4).
We exposed cells to TNFα for several hours and analysed
nuclear fractions (Figure 4a). It was possible to detect nuclear
accumulationofallNF-κBsubunitsandalsoasigniﬁcantincrease
in HIF-1α (Figure 4a). Furthermore, this prolonged TNFα
treatment also induced increases in two HIF target genes: GLUT1
and 3 (Figure 4b). To test whether the observed increases in HIF-
1α, GLUT1 and GLUT3 protein resulted from higher mRNA
levels, qRT-PCR was performed for the indicated times following
TNFα treatment. Interestingly, it was possible to observe an
increaseinHIF-1α,GLUT3andtoalesserextentGLUT1mRNA
with no change in HIF-2α mRNA (Figure 4c). These results
indicate that the HIF-1α and GLUT3 protein increases resulted
fromincreasedgenetranscription,whereastheincreaseinHIF-2α
levels was possibly due to protein stability effects. Furthermore,
siRNA-mediated depletion of HIF-1α or HIF-2α demonstrated
that TNFα-induced GLUT3 is HIF-1α-dependent (Figure 4d
and Supplementary Figure S1 at http://www.BiochemJ.org/bj/
412/bj4120477add.htm), indicating that TNFα-induced HIF-1α
is active transcriptionally.
TNFα-induced HIF-1α activity is NF-κB dependent
To test whether the observed changes in HIF-1α were NF-
κB dependent, siRNA for the different NF-κBs was combined
with TNFα treatment. Depletion of all of the subunits, with
the exception of p105/p50, resulted in an impairment of TNFα-
induced HIF-1α expression (Figure 5a). In addition, depletion
of HIF-1α r e s u l t e di ni m p a i r e dT N F α induction of PHD2
(Supplementary Figure S2 at http://www.BiochemJ.org/bj/412/
bj4120477add.htm), indicating that this is a HIF-1α-dependent
event. Furthermore, an inducible recruitment of HIF-1α to
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the promoters of some of its target genes was also detected
(Figure 5b).
To verify that TNFα was inducing changes at the HIF-1α pro-
moter, ChIPs were performed. It was possible to observe, follow-
ing 18 h of TNFα treatment, an active recruitment of RelA and
p52 to the HIF-1α promoter (Figure 5c). Importantly, TNFα
treatment did not induce NF-κB binding to a control region of the
HIF-1α gene. Furthermore, depletion of RelA, RelB, c-Rel and
p52 reduced TNFα-induced HIF-1α-mediated PHD2 induction
(Figure 5d). These results indicate that TNFα-induced changes in
HIF-1α levels and activity are NF-κB-dependent.
Complete block of the NF-κB activation pathway prevents
hypoxia-induced HIF-1α
Given that NF-κB can control basal HIF-1α mRNA levels, we
investigated whether blocking NF-κB could prevent hypoxia-
induced HIF-1. We took advantage of genetic knockout cells and
also used siRNA for the upstream kinase complex that regulates
NF-κB. We could observe that, when IKKα or IKKβ were
depleted, either by genetic knockout or siRNA-mediated silenc-
ing, there was very little effect on HIF-1α levels (Figures 6a and
6b), suggesting that protein stabilization can compensate for any
impairmentinthecanonicalornon-canonicalpathways.However,
when both IKKα and IKKβ were depleted, HIF-1 stabilization
in response to hypoxia was severely impaired (Figure 6c). This
suggests that HIF-1α gene transcription is mediated by several
subunits of NF-κB and these derive from both pathways of
activation. These results support our mRNA and ChIP results
on how NF-κB controls the HIF pathway. Given that hypoxia
does not induce increases in HIF-1α mRNA, it was not surprising
that no changes in NF-κB recruitment to the HIF-1α promoter
were observed following hypoxia treatment (Figure 6d). Once
again, we could not detect any NF-κB binding to a control region
of the HIF-1α gene (Figure 6d). These results suggest that any
impairment seen in HIF-1α stabilization following hypoxia, in
the absence of NF-κB, is due to changes in basal mRNA levels
and not due to a lack of an active induction of mRNA.
DISCUSSION
Chronic inﬂammation is self-perpetuating and has been shown
to distort the microenvironment as a result of aberrantly active
transcription factors. Consequent alterations in growth factor,
chemokine, cytokine and ROS balance within the cellular
milieu provide the axis of growth and survival needed for
de novo development of cancer and metastasis [25]. As such,
we hypothesized that novel interactions between two key
transcription factors, NF-κB and HIF, existed in this process.
In the present study, we demonstrate that HIF-1α basal mRNA
levels are controlled by several NF-κB subunits (Figures 1–3, 5
and 6). In addition, we show that TNFα-, and to some extent
hypoxia-, induced NF-κB regulates HIF-1α levels and activity,
triggering the transcription of target genes such as GLUT3 and
PHD2 (Figures 4–6).
Theresultsofthepresentstudyhavenumerousimplicationsfor
anumberofpathologieswhereNF-κBandHIF-1arederegulated,
such as rheumatoid arthritis or cancer. However, despite these
implications, NF-κB regulation of HIF-1α could be stimulus-
speciﬁc or even cell-type-speciﬁc. The evidence for this comes
from the available genetic knockout models. While HIF-1α
deletion results in embryonic lethality at day 9–11 [26,27], with
defects evident as early as 7 days, combined genetic deletion
of IKKα and IKKβ results in lethality at day 12 [28]. Single
deletions of IKKα, IKKβ or RelA result in lethality at much later
stages [28]. In HIF-1α
−/− mice, defects are seen in neural tube
formation, cardiovascular malformations and increases in cell
death in the cephalic mesemchyme. Of interest, IKKα/β double
null mice also have defects in neurulation, but these seem to be
associated with increased apoptosis in the neuronal epithelium. It
wouldbeinterestingtore-analysethesemiceembryosforHIF-1α
expression in the different tissues.
The results of the present study also demonstrate that TNFα
induces HIF-1 activity despite the presence of oxygen. TNFα can
produce ROS in cells [29] and these have been shown to inhibit
PHD activity [30,31]. Although we have not investigated this
possibility,thepresentresultsonHIF-1α stabilizationandactivity
would support this. Precise ROS measurements and PHD acti-
vity assays would answer these questions.
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